Kate Lurain

Viral oncologist and Lymphoma doc | Advocate for people living with HIV | #HIVonc | She/Her | My tweets are my own

[Kate Lurain @DrKateLurain]

Oncologists need to know how to harness a multidisciplinary team to care for people with #HIV and cancer

Some insights on #HIVonc

#ASCO23 @JCO_ASCO @NCIResearchCtr

https://t.co/9CgY6JLR6g

[WashU Medicine Division of Oncology @WashUOncology]

New research from @ThomasOdeny and team highlights the promise of immunotherapy for HIV-associated Kaposi sarcoma in treating KS in people living with HIV. #CancerResearch #HIV #Immunotherapy #KaposiSarcoma
Read More: https://t.co/mH5szdbuaT

[Michael Wagner @wagsmd]

IO can be safe and effective for HIV-KS. CITN12: Pembrolizumab in HIV-Associated Kaposi Sarcoma | ⁦@JCO_ASCO⁩ ⁦@DrKateLurain⁩ ��@EladSharonMD⁩ ⁦@ThomasUldrick⁩ https://t.co/BCLBIapqYN

[Thomas Uldrick, MD @ThomasUldrick]

Hot off the press from @DrKateLurain @ramya_ramaswami @ThomasOdeny @EladSharonMD @DiseaseDR Important new data showing high and durable activity for anti-PD1 in HIV-KS!
CITN12: Pembro in HIV-Associated Kaposi Sarcoma | JCO https://t.co/X9AtRySMUv

[Kate Lurain @DrKateLurain]

The future of oncology is bright! Inspiring to meet with superstar fellow @hsafaMD at #ASCO24

[Houssein Safa, MD @hsafaMD]

Had a fantastic time meeting @DrKateLurain at #ASCO24 last weekend. Our first in-person encounter, and I'm immensely grateful for her invaluable career advice. Mentorship takes many forms, and it's this supportive spirit that keeps our field thriving. Here’s to paying it forward!

[Kate Lurain @DrKateLurain]

@hsafaMD It was awesome meeting such a promising oncologist Dr. Safa!

[Thomas Uldrick, MD @ThomasUldrick]

Wish I were @ASH to see @DrKateLurain et al's important https://t.co/gJjhi4nH0F on CATCH-IT RWE for anti-PD1 in #HIV #Hodgkin #lymphoma today. Encouraging activity after med 2nd line Tx in EBV+ disease (unique biology in HIV ): 70% CR rate, 20 mo DOR including in low CD4!

[Kate Lurain @DrKateLurain]

Congrats to my dear friend and amazing clinician-scientist @ramya_ramaswami We couldn’t be luckier to have her brilliant research and compassionate care for our patients in the HIV and AIDS Malignancy Branch @NCIResearchCtr

[Kate Lurain @DrKateLurain]

@BioAscend @JaydiDelRivero @WeAreWLO Congrats @JaydiDelRivero !!!

[BioAscend @BioAscend]

Congratulations to our inspirational #LEAD2023 Rising Star @JaydiDelRivero @WeAreWLO

[Joe Ziegelbauer @DrJZ_]

I'm excited to share that our new paper is published. Many thanks to our wonderful team that made this possible. We are also grateful to the clinical trial participants for their contributions. #kshv #hhv8 #RNAseq #herpes #virus #OpenAccess https://t.co/QdeYby7Dcc

[Kate Lurain @DrKateLurain]

@NCITomMisteli @ASCBiology @NCIResearchCtr Congrats Dr. Misteli!

[Kate Lurain @DrKateLurain]

Excited to see the important results of BV-AVD in HIV+ Hodgkin lymphoma in print!

2-yr PFS 87% and OS 92% plus increases CD4/CD8 counts. Great work by Paul Rubinstein and @AMC_Studies

https://t.co/pGfjG0cvO6

[Kate Lurain @DrKateLurain]

@yanaastter @umichmedicine Congrats Yanna! Looking like a serious doctor already ❤️

[Christopher Melani @MelanicjMD]

Also such a wonderful group of caring and compassionate clinical researchers! Congrats on your achievements @DrKateLurain and @ramya_ramaswami 👏🏻

[Laercio DaSilva @laerciolopesMD]

Last in-person Friday didactics of the 2022-23 cycle, celebrating our ultra-dedicated chief @KrithikaShanm and her incoming🤰🏽👶 with a multi-national potluck 🇮🇳🇨🇲🇧🇷🇨🇦🇵🇰🇺🇸🇩🇪🇰🇷 🇮🇪 @HemOncFellows life @NCICCR_MOS

[Kate Lurain @DrKateLurain]

@camcanepi Thanks Cameron 😊

[Kate Lurain @DrKateLurain]

@ramya_ramaswami @NCIResearchCtr Thanks dear friend ❤️

[Sam M Mbulaiteye @SMbulaiteye]

Incidence of Burkitt lymphoma in the United States during 2000 to 2019 - PubMed: BL rates are multimodal- biological heterogeneity?; rates rose and fell-diagnostic or etiological factors? Survival improved by 20% points, but still low in black individuals. https://t.co/nvgePPACNQ

[Talal El Zarif, MD @TalalZarif1]

Very timely Oncology Grand Rounds @JCO_ASCO on HIV/ICI. Here, @DrKateLurain elegantly summarizes the literature w/ informative recommendations for clinical practice and presents a case of a person living with HIV + Hodgkin Lymphoma who had a complete response to Pembrolizumab.